{
  "ticker": "LLY",
  "target_date": "2025-07-07",
  "actual_date": "2025-07-07",
  "collected_at": "2025-12-08T11:58:54.956360",
  "price": {
    "open": 777.83,
    "high": 778.3,
    "low": 759.24,
    "close": 770.0452880859375,
    "volume": 2576900,
    "change_1d_pct": -1.0,
    "change_7d_pct": -2.45,
    "change_30d_pct": 6.61
  },
  "technicals": {
    "rsi_14": 31.98,
    "sma_20": 783.98,
    "sma_50": 774.99,
    "macd": 2.677,
    "macd_signal": 4.781,
    "macd_histogram": -2.103,
    "bb_upper": 816.65,
    "bb_lower": 751.32,
    "price_vs_sma20_pct": -1.78,
    "price_vs_sma50_pct": -0.64,
    "volume_ratio": 0.85
  },
  "fundamentals": {
    "market_cap": 893319184384,
    "pe_ratio": 48.824104,
    "forward_pe": 43.97617,
    "price_to_book": 37.518826,
    "price_to_sales": 15.034032,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.39,
    "pct_from_52w_low": 59.75
  },
  "macro": {
    "spy": {
      "price": 618.96,
      "change_1d_pct": -0.75,
      "change_7d_pct": 1.44
    },
    "vix": {
      "level": 17.79,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.39
    },
    "dollar_index": {
      "level": 97.48
    },
    "gold": {
      "price": 3332.2
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.",
      "source": "Yahoo",
      "datetime": 1751897303,
      "summary": "Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.",
      "url": "https://finnhub.io/api/news?id=b01039c43125e7dc61c0f0cb5955db61bce3c60800cfe350172b977d1f8cdbde"
    },
    {
      "headline": "PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center",
      "source": "SeekingAlpha",
      "datetime": 1751919820,
      "summary": "Eli Lilly and Johnson & Johnson, PPH\u00e2\u0080\u0099s largest holdings, are facing unique challenges, impacting the ETF\u00e2\u0080\u0099s overall performance. See why PPH ETF is a Hold.",
      "url": "https://finnhub.io/api/news?id=2e31dc19357d053976494413d5d0cfc2dd3f3beda3ad06d4d59b8757e2853b38"
    },
    {
      "headline": "Prime Medicine stock soars amid gene editing sector momentum",
      "source": "Yahoo",
      "datetime": 1751906915,
      "summary": "Investing.com -- Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly\u2019s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.",
      "url": "https://finnhub.io/api/news?id=cfc2bb0e477033a0add30efaeaffde8623f120a8eab3ddafbd304f87a6c0feb4"
    },
    {
      "headline": "Prime Medicine: Pressing Forward With Lead Liver Targeting Indications",
      "source": "SeekingAlpha",
      "datetime": 1751906707,
      "summary": "Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why PRME is a Buy.",
      "url": "https://finnhub.io/api/news?id=3d6bbd06b77f19c300342a70cf81ba3eb58ab6b778628abdc9361c0fc3086a05"
    },
    {
      "headline": "Novo and Lilly compete in India as obesity drugs demand hikes",
      "source": "Yahoo",
      "datetime": 1751896544,
      "summary": "STORY: :: Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market share.That\u2019s according to research firm Pharmarack.It said sales of Lilly's Mounjaro, which launched in March, doubled from May to June.Overall, it's almost hit close to",
      "url": "https://finnhub.io/api/news?id=c889944a026ac879ec3fa1490707b725e8f1e201620bb7e9dc2ab13377b88c72"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}